EVAX
Closed
Evaxion Biotech As
2.48
+0.03 (+1.22%)
Last Update: 01 Jul 2025 23:00:00
Yesterday: 2.45
Day's Range: 2.35 - 2.6
Send
sign up or login to leave a comment!
When Written:
1.13
Evaxion Biotech AS is a Danish biotechnology company that specializes in artificial intelligence (AI) and machine learning (ML) to develop vaccines and immunotherapies for infectious diseases, cancer, and other diseases. The company was founded in 2007 and is headquartered in Copenhagen, Denmark.
Evaxion's proprietary AI and ML platform, called the Evaxion Biotech Engine, is designed to analyze large amounts of genomic data and identify potential targets for vaccines and immunotherapies. The platform can also predict how the immune system will respond to these targets, allowing Evaxion to develop personalized treatments for individual patients.
The company's pipeline includes several vaccine candidates for infectious diseases such as COVID-19, influenza, and tuberculosis, as well as immunotherapies for cancer. Evaxion has partnerships with several pharmaceutical companies and research institutions to advance its pipeline and develop new treatments.
In 2021, Evaxion went public on the NASDAQ stock exchange through a merger with the special purpose acquisition company (SPAC) called ARYA Sciences Acquisition Corp II. The merger provided Evaxion with $75 million in funding to support its research and development efforts.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Evaxion's proprietary AI and ML platform, called the Evaxion Biotech Engine, is designed to analyze large amounts of genomic data and identify potential targets for vaccines and immunotherapies. The platform can also predict how the immune system will respond to these targets, allowing Evaxion to develop personalized treatments for individual patients.
The company's pipeline includes several vaccine candidates for infectious diseases such as COVID-19, influenza, and tuberculosis, as well as immunotherapies for cancer. Evaxion has partnerships with several pharmaceutical companies and research institutions to advance its pipeline and develop new treatments.
In 2021, Evaxion went public on the NASDAQ stock exchange through a merger with the special purpose acquisition company (SPAC) called ARYA Sciences Acquisition Corp II. The merger provided Evaxion with $75 million in funding to support its research and development efforts.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!